Genome Sequencer 20, based on 454 Sequencing technology, can perform sequencing runs up to 60 times faster than conventional commercially available platforms
The ultrafast Genome Sequencer 20 System from Roche Applied Science, a business area of Roche Diagnostics is taking more and more fields of life science research on board.
Most recent example: DYN, located at the Sheba medical center in Israel, will establish a center for sequencing services and post-sequencing analysis.
Backbone of the works will be its new Genome Sequencer 20 System recently purchased from Roche Applied Science.
DYN is aiming to become a specialised centre for providing sequencing services, focused on the 454 technology, and post-sequencing analysis turning the data to applicable scientific knowledge, cultivating advanced applications for medical diagnostics and research practice.
Its well-equipped lab was planned according to the 454 and Roche Diagnostics requirements.
Each step of the sequencing protocol is performed in a dedicated room with a high level of contamination precautions.
The company supports all the applications available from 454 and Roche Diagnostics, including whole genome sequencing, Paired-End, Amplicon, etc, and provides a tailor-made service according to their customers` requirements.
Furthermore, DYN invests efforts in acquiring new applications know-how and assigning them on the Genome Sequencer 20 System and is open to cooperation and collaborations.
"For us, the Genome Sequencer 20 System provides a rapid and efficient solution for sequencing of genomes," stated Relly Forer, DYN manager.
"We join the front line of Genomics by using this revolutionary technology and learn more about the future." "Although we as supplier of the Genome Sequencer 20 System have foreseen a big demand for this innovative system, we are surprised how fast the market is developing," said Manfred Baier, head of Roche Applied Science.
"The substantial reductions in both time and costs by using the system offer the prospect of new applications for sequencing in the fields of whole genome sequencing, transcriptome and gene regulation studies, or amplicon analysis e.g, as a basis for the detection of somatic mutations in cancer samples".
For post-sequencing analysis - assembling the reads, mapping the reads to a reference sequence, detecting the genes and assigning function to them, and revealing a global and local interpretation of the data - DYN will use its own bioinformatics.
Its bioinformatics utilises a collection of proven programs to annotate the sequence information along with an interface to browse, query and produce reports.
All the data is submitted to the customer in a user-friendly media, including: quality scores, raw-data reads assembly or mapping analyses, functional annotation and further analysis as required.
Since 2005, a new approach is available on the sequencing market, setting new standards in velocity and cost-effectiveness.
The Genome Sequencer 20 System, is based on 454 Sequencing technology, developed by the US company 454 Life Sciences, and can perform sequencing runs up to 60 times faster than conventional commercially available platforms.
For preparation of a whole genome, only one single preparation step, without extensive robots for colony picking and handling of the microtiter plates, is needed.
One single instrument can produce dozens of megabases of sequence data within a few hours, thanks to parallel-processing, the latest imaging techniques and unique data analysis.
For more information about the Sheba Medical Center, please click here.
